Iron Dextran and Systemic Lupus Erythematosus

Overview

Journal BMJ

Specialty General Medicine

Date 1992 Oct 24

PMID 1458107

Citations 3

Authors

V M Oh

Affiliations

Soon will be listed here.

Citing Articles

Intricating connections: the role of ferroptosis in systemic lupus erythematosus.

Zhao G, Li X, Zhang Y, Wang X, Deng L, Xu J Front Immunol. 2025; 16:1534926.

PMID: 39967676 PMC: 11832682. DOI: 10.3389/fimmu.2025.1534926.

Iron-dependent epigenetic modulation promotes pathogenic T cell differentiation in lupus.

Gao X, Song Y, Wu J, Lu S, Min X, Liu L J Clin Invest. 2022; 132(9).

PMID: 35499082 PMC: 9057600. DOI: 10.1172/JCI152345.

Iron Metabolism: An Under Investigated Driver of Renal Pathology in Lupus Nephritis.

Wlazlo E, Mehrad B, Morel L, Scindia Y Front Med (Lausanne). 2021; 8:643686.

PMID: 33912577 PMC: 8071941. DOI: 10.3389/fmed.2021.643686.

Intravenous ferric carboxymaltose is effective and safe in patients with inflammatory rheumatic diseases.

Salvadori U, Vittadello F, Al-Khaffaf A, Maier A, Cappelletto P, Daves M Blood Transfus. 2019; 18(3):176-181.

PMID: 31855154 PMC: 7250685. DOI: 10.2450/2019.0207-19.

References

Blake D, Lunec J, Ahern M, Ring E, Bradfield J, Gutteridge J . Effect of intravenous iron dextran on rheumatoid synovitis. Ann Rheum Dis. 1985; 44(3):183-8. PMC: 1001602. DOI: 10.1136/ard.44.3.183. View

Reddy P, Lewis M . The adverse effect of intravenous iron-dextran in rheumatoid arthritis. Arthritis Rheum. 1969; 12(4):454-7. DOI: 10.1002/art.1780120413. View

Hamstra R, BLOCK M, Schocket A . Intravenous iron dextran in clinical medicine. JAMA. 1980; 243(17):1726-31. View